ArticleFrontiers in immunology2026
Age-dependent immune profiles and variant-driven humoral alterations across two SARS-CoV-2 epidemic phases.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study investigates age-related immune differences during two SARS-CoV-2 epidemic phases and evaluates the neutralizing responses to the wild-type (WT) strain and XBB.1.5 following natural infection and vaccination. Methods: Throat swab and serum samples were collected from confirmed COVID-19 patients and contemporaneous healthy controls across different age groups during the B.1.1 and XBB epidemic peaks in Hebei Province, China. Serum immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies, viral load, key cytokines and variant-specific neutralizing capacity against WT and XBB.1.5 pseudoviruses were quantified using magnetic particle chemiluminescence, polymerase chain reaction (PCR), enzyme-linked immunosorbent assay (ELISA), and neutralization assays. Results: Humoral responses exhibited clear age dependence during both epidemic phases. Following B.1.1 infection, IgM levels peaked around week 3 and were lower in individuals under 18 years of age than in adults. IgG antibody levels increased over 5 weeks, reaching relatively higher concentrations in both infants (0-3 years) and older adults (≥60 years). Cytokine levels were lowest in the 3-18 years group and highest in those aged ≥60 years, consistent with their differential risks for severe disease. Both infection and vaccination induced neutralizing antibodies against the WT virus, but neutralization of XBB.1.5 was markedly reduced across all ages, indicating enhanced immune evasion. Vaccination elicited stronger neutralizing activity than natural infection alone, particularly in older adults, and provided the greatest relative improvement in cross-neutralization against XBB.1.5 in the ≥60 years group. Conversely, vaccinated individuals aged 3-18 years developed high antibody titers that did not translate into superior neutralization of XBB.1.5. Among unvaccinated infants, natural infection generated measurable neutralization of XBB.1.5, though efficacy remained limited. Conclusions: Immunological responses to SARS-CoV-2 and its variants differ substantially with age and immune history. Vaccination, especially in older adults, partially compensates for age-related immune decline and enhances cross-protection against immune-evasive variants such as XBB.1.5, supporting age-tailored vaccination and booster strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.